Cargando…

The Combination of Blueberry Juice and Probiotics Ameliorate Non-Alcoholic Steatohepatitis (NASH) by Affecting SREBP-1c/PNPLA-3 Pathway via PPAR-α

Nonalcoholic steatohepatitis (NASH) is liver inflammation and a major threat to public health. Several pharmaceutical agents have been used for NASH therapy but their high-rate side effects limit the use. Blueberry juice and probiotics (BP) have anti-inflammation and antibacterial properties, and ma...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ren, Tingting, Zhu, Juanjuan, Zhu, Lili, Cheng, Mingliang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5372861/ https://www.ncbi.nlm.nih.gov/pubmed/28264426 http://dx.doi.org/10.3390/nu9030198

Ejemplares similares

The combination of blueberry juice and probiotics reduces apoptosis of alcoholic fatty liver of mice by affecting SIRT1 pathway
por: Zhu, Juanjuan, et al.
Publicado: (2016)

Combined intake of blueberry juice and probiotics ameliorate mitochondrial dysfunction by activating SIRT1 in alcoholic fatty liver disease
por: Fan, Houmin, et al.
Publicado: (2021)

The monomer TEC of blueberry improves NASH by augmenting tRF-47-mediated autophagy/pyroptosis signaling pathway
por: Zhu, Juanjuan, et al.
Publicado: (2022)

Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice
por: Lindén, Daniel, et al.
Publicado: (2019)

Placental extract ameliorates non-alcoholic steatohepatitis (NASH) by exerting protective effects on endothelial cells
por: Yamauchi, Akihiro, et al.
Publicado: (2017)

PPAR Alpha as a Metabolic Modulator of the Liver: Role in the Pathogenesis of Nonalcoholic Steatohepatitis (NASH)
por: Todisco, Simona, et al.
Publicado: (2022)

The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH)
por: Mehta, Rohini, et al.
Publicado: (2016)

Pharmaceutical Efficacy of Gypenoside LXXV on Non-Alcoholic Steatohepatitis (NASH)
por: Lee, Jin Ha, et al.
Publicado: (2020)

Drugs for Non-alcoholic Steatohepatitis (NASH): Quest for the Holy Grail
por: Sharma, Mithun, et al.
Publicado: (2021)

SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy
por: Kim, Kwang-Youn, et al.
Publicado: (2016)

The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
por: Carpi, Rodrigo Zamignan, et al.
Publicado: (2022)

Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan
por: Park, Jung Gyu, et al.
Publicado: (2019)

Corrigendum: SREBP-2/PNPLA8 axis improves non-alcoholic fatty liver disease through activation of autophagy
por: Kim, Kwang-Youn, et al.
Publicado: (2016)

Molecular Mechanisms and New Treatment Strategies for Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2014)

Non-Alcoholic Steatohepatitis (NASH): Risk Factors in Morbidly Obese Patients
por: Losekann, Alexandre, et al.
Publicado: (2015)

Thrombospondin-I is a critical modulator in non-alcoholic steatohepatitis (NASH)
por: Min-DeBartolo, Jessica, et al.
Publicado: (2019)

Non-Alcoholic Steatohepatitis (NASH) and Organokines: What Is Now and What Will Be in the Future
por: dos Santos, João Paulo Margiotti, et al.
Publicado: (2022)

A New Potential Strategy for Acute Non-Alcoholic Steatohepatitis (NASH)
por: Sekhon, Anupamjeet Kaur, et al.
Publicado: (2021)

Deficiency of WTAP in hepatocytes induces lipoatrophy and non-alcoholic steatohepatitis (NASH)
por: Li, Xinzhi, et al.
Publicado: (2022)

Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
por: Ilan, Yaron
Publicado: (2018)

Increased Expression of RUNX1 in Liver Correlates with NASH Activity Score in Patients with Non-Alcoholic Steatohepatitis (NASH)
por: Kaur, Savneet, et al.
Publicado: (2019)

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
por: Gastaldelli, Amalia, et al.
Publicado: (2021)

Novel Combinatorial Regimen of Garcinol and Curcuminoids for Non-alcoholic Steatohepatitis (NASH) in Mice
por: Majeed, Muhammed, et al.
Publicado: (2020)

Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH
por: Bruschi, Francesca V., et al.
Publicado: (2020)

The Influence of Different Fat Sources on Steatohepatitis and Fibrosis Development in the Western Diet Mouse Model of Non-alcoholic Steatohepatitis (NASH)
por: Drescher, Hannah K., et al.
Publicado: (2019)

Role of Cholesterol‐Associated Steatohepatitis in the Development of NASH
por: Horn, Christian L., et al.
Publicado: (2021)

The burden of nonalcoholic steatohepatitis (NASH) in the United States
por: Tapper, Elliot B., et al.
Publicado: (2023)

Metabolomic Profiling to Identify Predictors of Response to Vitamin E for Non-Alcoholic Steatohepatitis (NASH)
por: Cheng, Jianfeng, et al.
Publicado: (2012)

Role of adipose tissue in methionine–choline-deficient model of non-alcoholic steatohepatitis (NASH)()
por: Jha, Pooja, et al.
Publicado: (2014)

Sorafenib prevents liver fibrosis in a non-alcoholic steatohepatitis (NASH) rodent model
por: Stefano, J.T., et al.
Publicado: (2015)

Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
por: Connolly, James J., et al.
Publicado: (2018)

A Structured Literature Review of the Epidemiology and Disease Burden of Non-Alcoholic Steatohepatitis (NASH)
por: Povsic, Manca, et al.
Publicado: (2019)

Genistein Modulated Lipid Metabolism, Hepatic PPARγ, and Adiponectin Expression in Bilateral Ovariectomized Rats with Nonalcoholic Steatohepatitis (NASH)
por: Pummoung, Sudaporn, et al.
Publicado: (2020)

A Novel Animal Model of Nonalcoholic Steatohepatitis (NASH): Hypoxemia Enhances the Development of NASH
por: Takayama, Fusako, et al.
Publicado: (2009)

Identification of Combined Genetic Determinants of Liver Stiffness within the SREBP1c-PNPLA3 Pathway
por: Krawczyk, Marcin, et al.
Publicado: (2013)

Dietary Supplementation of Blueberry Juice Enhances Hepatic Expression of Metallothionein and Attenuates Liver Fibrosis in Rats
por: Wang, Yuping, et al.
Publicado: (2013)

Capparis spinosa improves non-alcoholic steatohepatitis through down-regulating SREBP-1c and a PPARα-independent pathway in high-fat diet-fed rats
por: Akbari, Rasoul, et al.
Publicado: (2022)

Prevalence of Non Alcoholic Steatohepatitis (NASH) and association with body mass index in obese adolescents in Padang
por: Farlina, Lita, et al.
Publicado: (2013)

Multiple Hits, Including Oxidative Stress, as Pathogenesis and Treatment Target in Non-Alcoholic Steatohepatitis (NASH)
por: Takaki, Akinobu, et al.
Publicado: (2013)

Reliability and validity of the Chronic Liver Disease Questionnaire (CLDQ) in adults with non-alcoholic steatohepatitis (NASH)
por: Chawla, Kashmira S, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_raefri283oclcd85u7595b4f37